Protocol Ledger

NCT03779841 · Phase II · COMPLETED

Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)

Interventional Phase II clinical trial protocol NCT03779841 sponsored by AbbVie in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-03-01 Enrollment: 323 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03779841
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)323 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03779841
Protocol FieldVerified Registry Value
NCT IdentifierNCT03779841
Consolidated Lead SponsorAbbVie
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment323 participants (ACTUAL)
Registered Start Date2019-03-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI